{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:48:37Z","timestamp":1781560117308,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12872-016-0429-6","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T11:57:40Z","timestamp":1481111860000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Dov","family":"Shiffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre R.","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy Z.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance A.","family":"Bare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Melander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,7]]},"reference":[{"issue":"3","key":"429_CR1","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1161\/01.cir.0000441139.02102.80","volume":"129","author":"AS Go","year":"2014","unstructured":"Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28\u2013e292.","journal-title":"Circulation"},{"issue":"25 Pt B","key":"429_CR2","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1016\/j.jacc.2013.11.005","volume":"63","author":"DC Goff Jr","year":"2014","unstructured":"Goff Jr DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino Sr RB, Gibbons R, Greenland P, Lackland DT, Levy D, O\u2019Donnell CJ, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2935\u201359.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"429_CR3","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program Expert Panel on Detection E","year":"2002","unstructured":"National Cholesterol Education Program Expert Panel on Detection E. Treatment of High Blood Cholesterol in A: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143\u2013421.","journal-title":"Circulation"},{"key":"429_CR4","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"25 Pt B","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;25 Pt B:2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"429_CR5","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1377\/hlthaff.2011.1120","volume":"31","author":"DC Grabowski","year":"2012","unstructured":"Grabowski DC, Lakdawalla DN, Goldman DP, Eber M, Liu LZ, Abdelgawad T, Kuznik A, Chernew ME, Philipson T. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood). 2012;31(10):2276\u201385.","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"429_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/MOL.0b013e32833b7756","volume":"21","author":"RM Krauss","year":"2010","unstructured":"Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010;21(4):305\u201311.","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"429_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1161\/ATVBAHA.114.303458","volume":"34","author":"RM Krauss","year":"2014","unstructured":"Krauss RM. All low-density lipoprotein particles are not created equal. Arterioscler Thromb Vasc Biol. 2014;34(5):959\u201361.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"429_CR8","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.jacc.2015.02.077","volume":"65","author":"O Melander","year":"2015","unstructured":"Melander O, Shiffman D, Caulfield MP, Louie JZ, Rowland CM, Devlin JJ, Krauss RM. Low-density lipoprotein particle number is associated with cardiovascular events among those Not classified into statin benefit groups. J Am Coll Cardiol. 2015;65(23):2571\u20133.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"429_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1161\/CIRCULATIONAHA.111.035725","volume":"124","author":"AJ Kooter","year":"2011","unstructured":"Kooter AJ, Kostense PJ, Groenewold J, Thijs A, Sattar N, Smulders YM. Integrating information from novel risk factors with calculated risks: the critical impact of risk factor prevalence. Circulation. 2011;124(6):741\u20135.","journal-title":"Circulation"},{"key":"429_CR10","volume-title":"Modeling survival data in medical research","author":"D Collett","year":"2003","unstructured":"Collett D. In: Chapman & Hall\/CRC, editor. Modeling survival data in medical research. 12th ed. 2003.","edition":"12"},{"issue":"21","key":"429_CR11","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"9867","key":"429_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(13)60141-5","volume":"381","author":"FW Mohr","year":"2013","unstructured":"Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes Jr DR, Morel MA, Van Dyck N, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013;381(9867):629\u201338.","journal-title":"Lancet"},{"issue":"25","key":"429_CR13","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"3","key":"429_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1161\/STROKEAHA.114.007624","volume":"46","author":"S Greisenegger","year":"2015","unstructured":"Greisenegger S, Segal HC, Burgess AI, Poole DL, Mehta Z, Rothwell PM. Biomarkers and mortality after transient ischemic attack and minor ischemic stroke: population-based study. Stroke a j cereb circulation. 2015;46(3):659\u201366.","journal-title":"Stroke a j cereb circulation"},{"issue":"21","key":"429_CR15","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1001\/archinte.162.21.2405","volume":"162","author":"MR Law","year":"2002","unstructured":"Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med. 2002;162(21):2405\u201310.","journal-title":"Arch Intern Med"},{"issue":"5","key":"429_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/archinternmed.2011.2","volume":"171","author":"SG Wannamethee","year":"2011","unstructured":"Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011;171(5):404\u201310.","journal-title":"Arch Intern Med"},{"issue":"2","key":"429_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/j.1464-5491.2008.02640.x","volume":"26","author":"U Bulugahapitiya","year":"2009","unstructured":"Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? systematic review and meta-analysis. Diabet Med. 2009;26(2):142\u20138.","journal-title":"Diabet Med"},{"issue":"5","key":"429_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1001\/archinternmed.2010.524","volume":"171","author":"I Idris","year":"2011","unstructured":"Idris I. Diabetes and cardiovascular risk equivalency: do age at diagnosis and disease duration affect risk stratification?: comment on \u201cimpact of diabetes on cardiovascular disease risk and all-cause mortality in older men\u201d. Arch Intern Med. 2011;171(5):410\u20131.","journal-title":"Arch Intern Med"},{"issue":"8","key":"429_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2337\/diacare.23.8.1119","volume":"23","author":"E Brun","year":"2000","unstructured":"Brun E, Nelson RG, Bennett PH, Imperatore G, Zoppini G, Verlato G, Muggeo M, Verona Diabetes S. Diabetes duration and cause-specific mortality in the Verona diabetes study. Diabetes Care. 2000;23(8):1119\u201323.","journal-title":"Diabetes Care"},{"key":"429_CR20","unstructured":"Bureau of Labor Statistics. Consumer Price Index. Washington: US Department of Labor; 2014. Accessed 1 Apr 2015."},{"issue":"2","key":"429_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jama.2015.6822","volume":"314","author":"A Pandya","year":"2015","unstructured":"Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA. 2015;314(2):142\u201350.","journal-title":"JAMA"},{"issue":"4","key":"429_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26(4):410\u201320.","journal-title":"Med Decis Making"},{"issue":"15","key":"429_CR23","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253\u20138.","journal-title":"JAMA"},{"issue":"5","key":"429_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","volume":"31","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E. Consolidated health economic evaluation reporting standards (CHEERS) statement. Pharmacoeconomics. 2013;31(5):361\u20137.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"429_CR25","doi-asserted-by":"publisher","first-page":"e0138092","DOI":"10.1371\/journal.pone.0138092","volume":"10","author":"BZ Galper","year":"2015","unstructured":"Galper BZ, Wang YC, Einstein AJ. Strategies for primary prevention of coronary heart disease based on risk stratification by the ACC\/AHA lipid guidelines, ATP III guidelines, coronary calcium scoring, and C-reactive protein, and a global treat-All strategy: a comparative--effectiveness modeling study. PLoS One. 2015;10(9):e0138092.","journal-title":"PLoS One"},{"issue":"9","key":"429_CR26","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s11883-014-0438-9","volume":"16","author":"RC Deano","year":"2014","unstructured":"Deano RC, Pandya A, Jones EC, Borden WB. A look at statin cost-effectiveness in view of the 2013 ACC\/AHA cholesterol management guidelines. Curr Atheroscler Rep. 2014;16(9):438.","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"429_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7326\/0003-4819-144-5-200603070-00007","volume":"144","author":"M Pignone","year":"2006","unstructured":"Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006;144(5):326\u201336.","journal-title":"Ann Intern Med"},{"issue":"4","key":"429_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.7326\/0003-4819-150-4-200902170-00005","volume":"150","author":"MJ Pletcher","year":"2009","unstructured":"Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4):243\u201354.","journal-title":"Ann Intern Med"},{"issue":"2","key":"429_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1161\/CIRCULATIONAHA.110.986349","volume":"124","author":"LD Lazar","year":"2011","unstructured":"Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124(2):146\u201353.","journal-title":"Circulation"},{"issue":"2","key":"429_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/CIRCOUTCOMES.114.000886","volume":"7","author":"MA Hlatky","year":"2014","unstructured":"Hlatky MA. To test or not to test, that is the question. Circ Cardiovasc Qual Outcomes. 2014;7(2):207\u20138.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"429_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/CIRCOUTCOMES.113.000799","volume":"7","author":"MJ Pletcher","year":"2014","unstructured":"Pletcher MJ, Pignone M, Earnshaw S, McDade C, Phillips KA, Auer R, Zablotska L, Greenland P. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes. 2014;7(2):276\u201384.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"15","key":"429_CR32","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1161\/CIRCULATIONAHA.110.947960","volume":"122","author":"KK Lee","year":"2010","unstructured":"Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation. 2010;122(15):1478\u201387.","journal-title":"Circulation"},{"issue":"2","key":"429_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/CIRCOUTCOMES.114.001240","volume":"8","author":"R Hutchins","year":"2015","unstructured":"Hutchins R, Viera AJ, Sheridan SL, Pignone MP. Quantifying the utility of taking pills for cardiovascular prevention. Circ Cardiovasc Qual Outcomes. 2015;8(2):155\u201363.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"429_CR34","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/ehjci\/jev283","volume":"17","author":"M Iannaccone","year":"2016","unstructured":"Iannaccone M, Quadri G, Taha S, D\u2019Ascenzo F, Montefusco A, Omede P, Jang IK, Niccoli G, Souteyrand G, Yundai C, Toutouzas K, Benedetto S, Barbero U, Annone U, Lonni E, Imori Y, Biondi-Zoccai G, Templin C, Moretti C, Luscher TF, Gaita F. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2016;17(10):1128\u201337.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"429_CR35","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3111\/13696998.2010.499758","volume":"13","author":"RL Ohsfeldt","year":"2010","unstructured":"Ohsfeldt RL, Gandhi SK, Smolen LJ, Jensen MM, Fox KM, Gold A, Hsia J. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial. J Med Econ. 2010;13(3):428\u201337.","journal-title":"J Med Econ"},{"issue":"7","key":"429_CR36","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jacc.2010.07.059","volume":"57","author":"NK Choudhry","year":"2011","unstructured":"Choudhry NK, Patrick AR, Glynn RJ, Avorn J. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol. 2011;57(7):784\u201391.","journal-title":"J Am Coll Cardiol"},{"key":"429_CR37","unstructured":"Clinical Lab Fee Schedule, 2010 (10CLAB). www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/Clinical-Laboratory-Fee-Schedule-Files.html . Accessed 15 Apr 2015.\u00a0"},{"issue":"8","key":"429_CR38","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2165\/11584620-000000000-00000","volume":"29","author":"AK O\u2019Sullivan","year":"2011","unstructured":"O\u2019Sullivan AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011;29(8):693\u2013704.","journal-title":"Pharmacoeconomics"},{"key":"429_CR39","unstructured":"www.healthwarehouse.com . Accessed 1 Apr 2015."},{"key":"429_CR40","unstructured":"Trends in Use and Expenditures for Diabetes among Adults 18 and Older, U.S. Civilian Noninstitutionalized Population, 1996 and 2007. Statistical Brief #304. [ http:\/\/meps.ahrq.gov\/mepsweb\/data_files\/publications\/st304\/stat304.shtml ]. Accessed 15 Apr 2015."},{"issue":"25","key":"429_CR41","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"A Kashani","year":"2006","unstructured":"Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788\u201397.","journal-title":"Circulation"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-016-0429-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-016-0429-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-016-0429-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T09:01:22Z","timestamp":1568624482000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-016-0429-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1186\/s12872-016-0429-6","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"251"}}